Balyasny Asset Management
OLMA icon

Balyasny Asset Management’s Olema Pharmaceuticals OLMA Stock Holding History

Balyasny Asset Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89,671
Closed -$1.34M – 3371
2026
Q1 		$1.34M Sell
89,671
-77,637
-46% -$1.73M ﹤0.01% 1954
2025
Q4 		$4.18M Sell
167,308
-525,871
-76% -$9.36M 0.01% 1493
2025
Q3 		$6.79M Buy
+693,179
New +$4.16M 0.01% 1236
2025
Q2 		– Sell
-113,018
Closed -$425K – 3205
2025
Q1 		$425K Sell
113,018
-1,014,571
-90% -$5.1M ﹤0.01% 2335
2024
Q4 		$6.57M Buy
1,127,589
+418,492
+59% +$4.18M 0.01% 1140
2024
Q3 		$8.47M Buy
+709,097
New +$9.07M 0.01% 1034
2022
Q4 		– Sell
-12,097
Closed -$33K – 3096
2022
Q3 		$33K Buy
+12,097
New +$51.3K ﹤0.01% 2522

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Balyasny Asset Management's OLMA Position: Q2 2026 in Review

Balyasny Asset Management sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 89,671 shares — an estimated $1.34M sold.

Balyasny Asset Management first reported a position in OLMA in Q3 2022 and held it in 7 quarters. The position peaked at $8.47M in Q3 2024. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Balyasny Asset Management reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 89,671 Olema Pharmaceuticals shares in Q2 2026, an estimated $1.34M.
  • Balyasny Asset Management first reported a position in Olema Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Balyasny Asset Management's Olema Pharmaceuticals position peaked at $8.47M in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.